Key Laboratory for Space Bioscience and Biotechnology, Institute of Special Environmental Biophysics, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China.
Key Laboratory of Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an 710062, China.
Molecules. 2017 Jun 22;22(7):1033. doi: 10.3390/molecules22071033.
Drynariae Rhizoma is a kidney-tonifying herb that has a long history in clinical practice for the treatment of bone fractures and joint diseases in China. Flavonoids are considered to be its major active ingredients and are reported to ease bone loss in ovariectomized rats. However, the beneficial effects of the total flavonoids of Drynariae Rhizoma on osteoporosis caused by microgravity or mechanical inactivity remain unknown. This study assessed the effects of total Drynariae Rhizoma flavonoids (DRTF, Qihuang, Beijing, China, national medicine permit No. Z20030007, number of production: 04080081, content of DRTF ≥80%) against bone loss induced by simulated microgravity. A hindlimb unloading tail-suspended rat model was established to determine the effect of DRTF on bone mineral density (BMD), biomechanical strength and trabecular bone microarchitecture. Twenty-eight male Sprague-Dawley rats were divided into four groups: the baseline, control, hindlimb unloading with vehicle (HLU), and hindlimb unloading treated with DRTF (HLU-DRTF, 75 mg/kg/day) groups. Oral DRTF was administered for 4 weeks. The underlying mechanisms of the DRTF actions on disuse-induced osteoporosis are discussed. The results showed that DRTF treatment significantly increased the BMD and mechanical strength of tail-suspended rats. Enhanced bone turnover markers with HLU treatment were attenuated by DRTF administration. Deterioration of trabecular bone induced by HLU was prevented through elevated bone volume/tissue volume (BV/TV), trabecular number (Tb. N), trabecular thickness (Tb. Th) and decreased trabecular separation (Tb. Sp). The present study provides the first evidence that DRTF prevents bone loss induced by HLU treatment, indicating its potential application in the treatment of disuse-induced osteoporosis.
骨碎补是一种补肾草药，在中国临床上有治疗骨折和关节疾病的悠久历史。黄酮类化合物被认为是其主要活性成分，并被报道可缓解去卵巢大鼠的骨质流失。然而，骨碎补总黄酮对由微重力或机械性不活动引起的骨质疏松症的有益作用尚不清楚。本研究评估了总骨碎补黄酮（DRTF，奇黄，北京，中国，国家药品许可证号 Z20030007，生产编号 04080081，DRTF 含量≥80%）对模拟微重力诱导的骨丢失的作用。建立后肢去负荷尾部悬吊大鼠模型，以确定 DRTF 对骨密度（BMD）、生物力学强度和小梁骨微结构的影响。将 28 只雄性 Sprague-Dawley 大鼠分为四组：基线组、对照组、后肢去负荷加载体（HLU）组和后肢去负荷加 DRTF（HLU-DRTF，75mg/kg/天）组。DRTF 经口给药 4 周。讨论了 DRTF 对废用性骨质疏松作用的潜在机制。结果表明，DRTF 治疗可显著增加尾部悬吊大鼠的 BMD 和机械强度。DRTF 给药可减弱 HLU 治疗引起的骨转换标志物升高。DRTF 给药可通过增加骨体积/组织体积（BV/TV）、小梁数（Tb.N）、小梁厚度（Tb.Th）和降低小梁间距（Tb.Sp）来预防 HLU 引起的小梁骨恶化。本研究首次提供了 DRTF 可预防 HLU 治疗引起的骨丢失的证据，表明其在治疗废用性骨质疏松症方面具有潜在的应用价值。
